在结性脊柱炎患者的生物治疗现状和一些相关因素
Bui Hai Binh1, Nguyen Ngoc Trung2, Nguyen-Van Hung1,3
1Rheumatology, Bach Mai Hospital, Hanoi, Vietnam.
Materia socio-medica
|October 5, 2023
概括
在越南,对结性脊柱炎的生物药物治疗显示,随着时间的推移,治疗率正在下降. 大多数患者因缺乏反应或成本而转换或停止药物治疗,而年龄会影响药物的服药.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 轴性脊柱关节炎 (axSpA) 是一种致残的炎症性脊柱关节炎,通常在45岁之前开始.
- 它表现为慢性背痛,并可能涉及关节特征,如突炎和肠炎.
- 相关的非关节性特征包括脑膜炎,牛皮和炎症性肠病.
研究的目的:
- 描述目前在越南治疗结性脊柱炎的生物药物的使用情况.
- 确定影响这些患者生物药物治疗的因素.
主要方法:
- 一项描述性的横截面研究,涉及161名用生物治疗的结性脊柱炎患者.
- 从2018年1月到2021年7月收集的前性和后性数据.
- 包括一般,临床和准临床特征以及36个月的药物使用状况.
主要成果:
- 因弗利克西马布是最常见的第一线生物药物 (44.7%).
- 生物治疗率从基线时的100%下降到3年后的39.1%.
- 药物变化 (74%) 和停药 (50%由于成本) 是常见的;年龄与坚持相关.
结论:
- 因弗利西马布是主要的生物选择,但持续治疗具有挑战性.
- 药物修改和停药的高率是由不响应和经济因素驱动的.
- 在接受生物药物治疗的结性脊柱炎患者中,年龄会影响治疗的坚持.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
137
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
137
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
154
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
154
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
178
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
178
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
341
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
341
Drugs for Treatment of Ulcerative Colitis in IBD
156
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
156
Factors Affecting Drug Biotransformation: Biological
162
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
162


